A series of chiralsulfahydantoins have been synthesized by alkaline cyclization starting from N-sulfamylaminoacid methyl esters. Regioselective glycosylation of these pseudopyrimidic heterocycles was carried out with a benzyl protecting group on the N-sulfonylcarbamic position. Best glycosylation results were obtained by preliminary silylation of sulfahydantoins, and their condensation with a tetraacylribofuranose
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
申请人:ENANTA PHARMACEUTICALS, INC.
公开号:US10457703B2
公开(公告)日:2019-10-29
The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof,
The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
本发明提供了式 I 所代表的化合物或其药学上可接受的盐、立体异构体、溶液剂、水合物或其组合、
本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
申请人:Enanta Pharmaceuticals, Inc.
公开号:EP3277286A1
公开(公告)日:2018-02-07
[EN] BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS D'ACIDE BILIAIRE UTILISÉS COMME AGONISTES DE FXR/TGR5 ET LEURS PROCÉDÉS D'UTILISATION
申请人:ENANTA PHAMRACEUTICALS INC
公开号:WO2016161003A1
公开(公告)日:2016-10-06
The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, (I). The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Unprecedented directed oxidative cross-coupling of sulfahydantoins with aldehydes via a radical sulfonate–sulfinate conversion
作者:Yoann Aubin、Evelina Colacino、Djamel Bouchouk、Isabelle Chataigner、María del Mar Sánchez、Jean Martinez、Georges Dewynter
DOI:10.1039/c2nj40294g
日期:——
An unexpected CâC cross-coupling radical oxidation involving aldehydes and glycine enolate equivalents such as activated mesyl-sulfahydantoins leading to β,βâ²-disubstituted aspartate semialdehydes (ASA) instead of the expected threonine analogues was observed and various α-substituted non-proteinogenic amino acid analogues were synthesized. A radical mechanism was envisaged and supported by DFT calculations.